Hyperbaric Oxygen Therapy Associated with Ventricular–Subcutaneous Shunt Promotes Neuroprotection in Young Hydrocephalic Rats

Objective: In this study, the research team aimed to explore the therapeutic effectiveness of hyperbaric oxygen therapy (HBOT) for noise-induced hearing loss (NIHL), its influence on patient prognosis, and its impact on hearing to provide valuable clinical evidence. Methods: Ninety-four patients with NIHL admitted to The First People’s Hospital of Changde City, Hunan, China, from May 2021 to January 2023 were selected for this retrospective analysis. Among them, 43 were given conventional treatment (control group) and 51 were given HBOT (observation group). The clinical efficacy, symptom improvement, and pure-tone hearing thresholds (PTHTs) at different frequencies were detected. All cases were followed up for 12 months to record the NIHL recurrence rates and hearing (hearing threshold), and their quality of life was investigated. Results: The observation group had higher total effective rate and excellent rate and lower incidence of insomnia, tinnitus, and other symptoms than the control group (P < 0.05). PTHTs were lower in the observation group than in the control group at different frequencies (P < 0.05). Follow-up analysis showed no notable intergroup difference in the NHL recurrence rate (P > 0.05), but the hearing threshold was lower and the quality of life was better in the observation group than in the control group (P < 0.05). Conclusions: Compared to conventional treatment, HBOT is effective in treating NIHL and can improve the hearing and coagulation function of patients and provide a reliable guarantee for their prognostic health.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Hyperbaric Oxygen Therapy Associated with Ventricular–Subcutaneous Shunt Promotes Neuroprotection in Young Hydrocephalic Rats

Cited by 3 publications

References 56 publications

Memantine associated with ventricular-subcutaneous shunt promotes behavioral improvement, reduces reactive astrogliosis and cell death in juvenile hydrocephalic rats

Memantine associated with ventricular-subcutaneous shunt promotes behavioral improvement, reduces reactive astrogliosis and cell death in juvenile hydrocephalic rats

Celecoxib attenuates neuroinflammation, reactive astrogliosis and promotes neuroprotection in young rats with experimental hydrocephalus

Analysis of the positive influence of hyperbaric oxygen therapy on the prognosis and hearing control of patients with noise-induced hearing loss

Contact Info

Product

Resources

About